ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO866

Unveiling the Second Hit: Cytomegalovirus-Induced Collapsing Glomerulopathy in a Patient with Lupus

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Bollavaram, Vidya K., Geisinger Medical Center, Danville, Pennsylvania, United States
  • Gonter, Aric, Geisinger Medical Center, Danville, Pennsylvania, United States
  • Bermudez, Maria, Geisinger Medical Center, Danville, Pennsylvania, United States
  • Kalra, Kartik, Geisinger Medical Center, Danville, Pennsylvania, United States
Introduction

Collapsing glomerulopathy (cGN) is a histological type of focal segmental glomerulosclerosis (FSGS) best described in association with human immunodeficiency virus (HIV). It has been increasingly seen in association with drugs, autoimmune disease, viruses (SARS-CoV2), and in rare cases, with cytomegalovirus (CMV). We present the case of a patient with lupus found to have cGN in the setting of CMV viremia.

Case Description

A 33-year-old African American female with a history of biopsy-proven Class V lupus maintained on hydroxychloroquine and mycophenolate, presented with 1 week of dyspnea and fevers. Lab investigations revealed Serum Creatinine (Cr) of 2.7 mg/dL (baseline 1.1mg/dL), pancytopenia, low C3 (80mg/dL), and C4 (7mg/dL) with negative dsDNA. Urinalysis showed 5-10 RBC. Spot urine Protein/Cr ratio was 10 gm/gm. Her clinical course was complicated by diarrhea and worsening acute kidney injury (AKI) requiring dialysis. The etiology of AKI was initially thought to be a lupus flare, and a kidney biopsy was done. Biopsy showed podocyte hyperplasia, collapse of the underlying glomerular tuft with segmental glomerulosclerosis, 40% interstitial fibrosis, and tubular atrophy. No evidence of an active immune complex-mediated process was noted. Viral studies were positive for CMV (CMV DNA 1,310,085 IU/ml). The patient was started on high-dose steroids and valganciclovir while other immunosuppression was held.

Discussion

cGN represents a variant of FSGS typically presenting with severe nephrosis and AKI. In our case, CMV likely acted as a ‘second hit’ with a possible underlying high-risk APOL-1 gene mutation, given her ancestry. The mechanism driving development of cGN has been proposed to be mediated by an interferon-chemokine pathway. Second hits such as HIV or SARS-CoV2 activate an inflammatory cascade that interacts with high-risk APOL-1 variants to precipitate cGN. Lupus has been associated with high interferon activity and thus may be another predisposing factor. CMV overall, remains a rare cause for cGN. While flares and class switching are sound differentials for AKI in lupus patients, this case highlights the importance of testing for CMV and considering cGN as a cause for AKI, especially in patients with African American ancestry. It further emphasizes the importance of ruling out opportunistic infections before preemptively adding more immunosuppression.